FDA has strongly recommended drug master files arrive much earlier than initial estimates to avoid delaying the referencing ANDA, likely requiring more extensive planning for sponsors and further complicating the review process for both submissions.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?